title: Photodynamic treatment in a rabbit model of glaucoma surgery.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of postoperative verteporfin photodynamic treatment as an adjunct to glaucoma experimental filtration surgery in rabbits.
  
  
  METHODS
  Dutch belted (n = 15) rabbits underwent full thickness sclerectomy in one eye. The experimental group (group 1, n = 7) underwent i.v. injection of verteporfin and subsequent photoactivation at the operative site on postoperative day 1 (POD 1). Control groups of animals received either light exposure (group 2, n = 4) or verteporfin (group 3, n = 2), or no intervention (group 4, n = 2). Intraocular pressure (IOP) was measured prior to the procedure (POD 0) and daily thereafter for the first week after sclerectomy (PODs 1-7) and every other day for the second week (PODs 9, 11, 13, 15). Percentage IOP reductions of operated over contralateral control eyes were compared among the various groups. Success rates (percentage IOP reduction > 15%) were also compared between the experimental and control groups. Eyes were histologically examined for evaluation of fibrosis.
  
  
  RESULTS
  Rabbits in the experimental group (group 1) had a mean +/- SEM percentage IOP reduction of 25 +/- 3% during the follow-up period. In contrast, groups 2, 3 and 4 had IOP reductions of 4 +/- 5%, 12 +/- 7% and 4 +/- 6%, respectively (p < 0.005, anova among all four groups). Successful IOP reduction (> or = 15%) over the contralateral eye at POD 15 was achieved in six of seven experimental animals, but only in one of eight control animals (p < 0.02, chi-squared test). Bleb failure occurred significantly earlier in the control eyes compared with eyes receiving PDT (p < 0.003, log rank test). Blebs in the experimental group differed from those in the control groups histologically, lacking significant collagen deposition in the area of the sclerostomy.
  
  
  CONCLUSIONS
  Wound healing in glaucoma surgery may be successfully modulated postoperatively using photodynamic therapy with i.v. administered photosensitizer.
authors.affiliation: Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York 10029, USA.
authors.forename: Kalliopi
authors.initials: K
authors.lastname: Stasi
authors.forename: Jeff
authors.initials: J
authors.lastname: Paccione
authors.forename: Glen
authors.initials: G
authors.lastname: Bianchi
authors.forename: Alan
authors.initials: A
authors.lastname: Friedman
authors.forename: John
authors.initials: J
authors.lastname: Danias
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D005901:Glaucoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D007262:Infusions, Intravenous; D007429:Intraocular Pressure; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011817:Rabbits; D012599:Sclerostomy; D000077362:Verteporfin; D014945:Wound Healing
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin